Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552748 | 0.78 | ACHE (0.43) | ACHEKIF11PDE7ACA1CA2 | |
| SCHEMBL3668657 | 0.74 | ACHE (0.46) | ACHEKIF11CA1CA2CA7 | |
| SCHEMBL803441 | 0.73 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL24105727 | 0.73 | ACHE (0.50) | ACHEPDK2CA1CA2CA7 | |
| SCHEMBL22024000 | 0.72 | ACHE (0.44) | ACHEKIF11PDE7ACA1CA2 | |
| SCHEMBL22989913 | 0.71 | ACHE (0.48) | ACHEPDK2CA1CA2CA7 | |
| SCHEMBL4553968 | 0.69 | ACHE (0.50) | ACHEPDK2CA1CA2CA7 | |
| SCHEMBL19618115 | 0.65 | RIPK1 (0.40) | ACHE | |
| SCHEMBL20250030 | 0.64 | KAT6A (0.41) | ACHE | |
| SCHEMBL20250032 | 0.63 | KAT6A (0.40) | ACHEPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194917-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194917-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | ESR1, ESR2, GPER1 | ACHE 4788/4885KIF11 4172/4885PDE7A 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.